Literature DB >> 34131243

Susceptibility of cyclin-dependent kinase inhibitor 1-deficient mice to rheumatoid arthritis arising from interleukin-1β-induced inflammation.

Yoshinori Takashima1, Shinya Hayashi2, Koji Fukuda1, Toshihisa Maeda1, Masanori Tsubosaka1, Tomoyuki Kamenaga1, Kenichi Kikuchi1, Masahiro Fujita1, Yuichi Kuroda1, Shingo Hashimoto1, Naoki Nakano1, Tomoyuki Matsumoto1, Ryosuke Kuroda1.   

Abstract

We recently reported that cyclin-dependent kinase inhibitor 1 (p21) deficiency induces osteoarthritis susceptibility. Here, we determined the mechanism underlying the effect of p21 in synovial and cartilage tissues in RA. The knee joints of p21-knockout (p21-/-) (n = 16) and wild type C57BL/6 (p21+/+) mice (n = 16) served as in vivo models of collagen antibody-induced arthritis (CAIA). Arthritis severity was evaluated by immunological and histological analyses. The response of p21 small-interfering RNA (siRNA)-treated human RA FLSs (n = 5 per group) to interleukin (IL)-1β stimulation was determined in vitro. Arthritis scores were higher in p21-/- mice than in p21+/+ mice. More severe synovitis, earlier loss of Safranin-O staining, and cartilage destruction were observed in p21-/- mice compared to p21+/+ mice. p21-/- mice expressed higher levels of IL-1β, TNF-α, F4/80, CD86, p-IKKα/β, and matrix metalloproteinases (MMPs) in cartilage and synovial tissues via IL-1β-induced NF-kB signaling. IL-1β stimulation significantly increased IL-6, IL-8, and MMP expression, and enhanced IKKα/β and IκBα phosphorylation in human FLSs. p21-deficient CAIA mice are susceptible to RA phenotype alterations, including joint cartilage destruction and severe synovitis. Therefore, p21 may have a regulatory role in inflammatory cytokine production including IL-1β, IL-6, and TNF-α.

Entities:  

Year:  2021        PMID: 34131243     DOI: 10.1038/s41598-021-92055-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  43 in total

Review 1.  Targeting interleukin-1 in the treatment of rheumatoid arthritis.

Authors:  Jean-Michel Dayer; Barry Bresnihan
Journal:  Arthritis Rheum       Date:  2002-03

2.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation.

Authors:  Meilang Xue; Kelly McKelvey; Kaitlin Shen; Nikita Minhas; Lyn March; Sang-Youel Park; Christopher J Jackson
Journal:  Rheumatology (Oxford)       Date:  2014-06-29       Impact factor: 7.580

4.  Analysis of the histologic variation of synovitis in rheumatoid arthritis.

Authors:  M Rooney; D Condell; W Quinlan; L Daly; A Whelan; C Feighery; B Bresnihan
Journal:  Arthritis Rheum       Date:  1988-08

Review 5.  Synovial fibroblasts: key players in rheumatoid arthritis.

Authors:  L C Huber; O Distler; I Tarner; R E Gay; S Gay; T Pap
Journal:  Rheumatology (Oxford)       Date:  2006-03-27       Impact factor: 7.580

6.  Progression of radiological changes in rheumatoid arthritis.

Authors:  D L Scott; K A Grindulis; G R Struthers; B L Coulton; A J Popert; P A Bacon
Journal:  Ann Rheum Dis       Date:  1984-02       Impact factor: 19.103

Review 7.  The role of cytokines in the pathogenesis of rheumatoid arthritis--Practical and potential application of cytokines as biomarkers and targets of personalized therapy.

Authors:  Edyta Brzustewicz; Ewa Bryl
Journal:  Cytokine       Date:  2015-08-29       Impact factor: 3.861

8.  Synovial fibroblasts spread rheumatoid arthritis to unaffected joints.

Authors:  Stephanie Lefèvre; Anette Knedla; Christoph Tennie; Andreas Kampmann; Christina Wunrau; Robert Dinser; Adelheid Korb; Eva-Maria Schnäker; Ingo H Tarner; Paul D Robbins; Christopher H Evans; Henning Stürz; Jürgen Steinmeyer; Steffen Gay; Jürgen Schölmerich; Thomas Pap; Ulf Müller-Ladner; Elena Neumann
Journal:  Nat Med       Date:  2009-11-08       Impact factor: 53.440

9.  Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts.

Authors:  M P Vincenti; C I Coon; C E Brinckerhoff
Journal:  Arthritis Rheum       Date:  1998-11

Review 10.  Cytokines in the pathogenesis of rheumatoid arthritis.

Authors:  Iain B McInnes; Georg Schett
Journal:  Nat Rev Immunol       Date:  2007-06       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.